### ESTP Newsletter 2025 (2)

Editor: Amy Narewski

Administrative Assistant to the ESTP Executive Committee

(ESTP contact link: <a href="https://www.eurotoxpath.org/contact.php">https://www.eurotoxpath.org/contact.php</a>)



<u>Content</u>	
Calendar	1
The ESTP Council	2
President's Column	2
2 <sup>nd</sup> BSTP/ESTP Joint Toxicologic Pathology Congress	4
Toxicologic Pathology Training Program – the next step	5
Introducing Kerstin Hahn: New ESTP Tox Path Journal Liaison	6
Pathology 2.0 Committee Year-End Meeting	7
The future of "Guess What": Results from the Survey and Thoughts for a New Concept	7
2025 ESTP Publication Award – Call for Papers or Theses	9
Reflections on the Classic Examples in Toxicologic Pathology XXXII	10
Announcement from the SFPT	12

	2025
	TiHo Hannover (sponsored by ESTP): Residency Program, Toxicologic Pathology
May 09-10	Training Program, Module "General Introduction into Toxicopathology",
	Hannover, Germany <u>LINK</u>
May 14-15	SFPT Annual scientific meeting "Leveraging the immune system: success, pitfalls
	and future" Vitry sur Seine (Paris), France LINK
June 22-25	STP 44th Annual Symposium: Toxicologic Neuropathology - Basics and Beyond:
	"Effective animal-to-human translation in neurotherapeutic development",
	Chicago, Illinois, USA <u>LINK</u>
June 30- July 2	RITA Panel Meeting, virtual meeting <u>LINK</u>
July 1-10	<b>BSTP</b> Virtual Continuing Education Symposium 12: Cardiovascular System, Virtual
	meeting <u>LINK</u>
September 22	<b>ESTP</b> Expert Workshop: "Pathologic effects in the female reproductive system:
	Determinants of adversity for findings in nonclinical toxicity studies and
	considerations for integrated risk assessment." Manchester, UK <u>LINK</u>
September 23	IATP Satellite Symposium: Pathology Working Groups (PWG) in Toxicologic
	Pathology <u>LINK</u>
September 23-26	<b>ESTP</b> 2nd joint congress of ESTP and BSTP - Carcinogenicity in the 21st Century:
	Challenges of New Methodologies, Strategies, and their Impact on Pathologists,
	Manchester, UK, <u>LINK</u>
October 8-10	Hungarian Toxicologic Society Annual Congress TOX'2025, Mátraháza, Hungary

#### The ESTP council

Chairperson	Vanessa Schumacher	Secretary	Raffaella Capobianco
Vice President	Lars Mecklenburg	Treasurer	Kuno Würsch
Past Chairperson	Silvia Guionaud	Designated Chairperson	Neus Prats
Congress Councillor	Anna-Lena Frisk	Councillor for Digital Pathology	Lise Bertrand
Councillor to represent University Teachers	Ingo Gerhauser	Councillor for Residents and Early Career Pathologists	Laura Polledo
Councillor for Nomenclature	Ute Bach	Councillor for Electronic Communication	Rupert Kellner
Councillor for Classic Examples	Thomas Nolte	NTP Representative	Eveline de Rijk
BSTP Representative	Zuhal Dincer	SFPT Representative	Céline Thuilliez
Hungarian STP Representative	György Selenyi	Chair, awards committee	Theresa Brömel
STP liaison, chair of the Scientific and Regulatory Standards Committee	Annette Romeike	Chair, clinical pathology committee	Monika Keresztes
Chair, Pathology 2.0 working group	Dirk Schaudien	ToxPath Journal Liaison	Kerstin Hahn
Admin Assistant to the ESTP EC	Amy Narewski		

#### President's Column

Dear Members,

As spring brings new growth and energy, our society is also buzzing with activity and initiatives. As you will read in this newsletter, we are pleased to share important updates and announcements from our society. Please consider one (or more!) of the many opportunities to engage as an active member of the ESTP. We count on our diverse and committed member community to further our society's impact.

I recently attended the Classic Examples in Toxicologic Pathology XXXII meeting in Hannover along with many of you, and it was a wonderful opportunity to connect and learn together with engaging cases and discussions. I appreciated the engagement of all participants,

and the opportunity to learn more about the research presented by the students of the veterinary school. Kudos to **Charlotte Lempp** and **Thomas Nolte** for the fantastic organization and facilitation, and many thanks to the presenters and their companies for sharing their examples.

Looking forward, we are excited to invite you to the Joint BSTP/ESTP **Toxicologic** Pathology Congress in Manchester, UK, from September 23-26, 2025. This will be the ESTP's 22<sup>nd</sup> congress, and we get to celebrate the BSTP's 40<sup>th</sup> congress with them! The theme is 21<sup>st</sup>"Carcinogenicity in the Century: Challenges of new methodologies, strategies, and their impact on pathologists". The scientific organizing committee has developed a vibrant program exploring current and emerging approaches for carcinogenicity evaluation, and you can be a part! Visit www.bstp-estpcongress.eu for details on the congress, and information on where you can submit an abstract for a case presentation or poster. Preceding and following the congress, an IATP symposium on Pathology Working Groups and an ESTP expert workshop on Female Reproductive System will be held.

Regarding our **Toxicologic Pathology Training Program**, the next cycle will run from summer semester 2025 to winter semester 2027/28, featuring 12 modules in Hannover, Barcelona, and Bern, with hybrid options for online participation. Details are available at <a href="https://www.tiho-hannover.de/kliniken-institute/institute/institut-fuer-pathologie/aktuelle-">https://www.tiho-hannover.de/kliniken-institute/institute/institut-fuer-pathologie/aktuelle-</a>

veranstaltungen/toxicologic-pathology-trainingprogram. This cycle comes with an exciting change: ECVP residents from training centers across Europe are eligible to attend. If you are interested in contributing to the program, please get in touch with the organizers.

We welcome **Kerstin Hahn** as our new ESTP Toxicologic Pathology Journal Liaison. Let's wish her lots of success in the new role!

The **Pathology 2.0 Committee** can proudly look back on 2024 with two manuscripts accepted for publication, as well as the honor of receiving the Toxicologic Pathology Review of the year Award 2023 for "European Society of Toxicologic Pathology (Pathology 2.0 Molecular Pathology Special Interest Group): Review of In Situ Hybridization Techniques for Drug Research and Development".

The committee also kicked off the Career Transition Support Group following a webinar on the topic and interest from our membership. The group will continue to explore educational opportunities to support our community on this topic.

The "Guess What" section of our website has faced low participation. To ensure we continue to provide meaningful learning opportunities, we are considering changes to the current format and we welcome ideas and suggestions.

The **2025 ESTP Publication Award** call for submissions is now open for publications from 2024-2025. The deadline is May 31, 2025. The award will be presented at the 2025 ESTP annual meeting in Manchester. Contact Dr. Theresa Brömel for submissions. Take the opportunity to nominate the work of yourself or your colleagues!

Finally, the **SFPT society** will hold its annual congress on May 14 and 15, 2025, at Sanofi's facility in Vitry sur Seine near Paris. The scientific program is available at <a href="https://toxpathfrance.org/congres/">https://toxpathfrance.org/congres/</a>.

As you can see, our society is continuously evolving, and we count on our members to take an active role, big or small,. We highly value your participation and continued engagement.

Sincerely,

Vanessa Schumacher ESTP Chairperson

### 2<sup>nd</sup> BSTP/ESTP Joint Toxicologic Pathology Congress

Carcinogenicity in the 21<sup>st</sup> Century: challenges of new methodologies, strategies, and their impact on pathologists

### 23 – 26 September 2025; Manchester, United Kingdom

Dear colleagues and friends,

The British Society of Toxicologic Pathology (BSTP) and The European Society of Toxicologic Pathology (ESTP) are pleased to invite you to the 2<sup>nd</sup> Joint BSTP/ESTP Toxicologic Pathology Congress entitled 'Carcinogenicity in the 21<sup>st</sup> Century: Challenges of new methodologies, strategies, and their impact on pathologists'.

The Scientific Organizing Committee (SOC) comprising both nationally and internationally recognized experts has prepared an excellent program. The invited speakers will review the best practices and the current status of carcinogenicity testing, discuss its limitations, and look to the future for new and emerging approaches including in silico, in vitro and ex vivo technologies for carcinogenicity evaluation of agrochemical and pharmaceuticals. carcinogenetic Predicting potential compounds at early stages, and carcinogenicity assessment of new modality drugs, and risk assessment and human relevance of neoplastic and non-neoplastic findings will be featured through plenary lectures, oral presentations, case studies, and panel discussions. For details,

including how to submit abstracts for case presentations and posters, please visit the congress website: <a href="www.bstp-estp-congress.eu">www.bstp-estp-congress.eu</a>

In conjunction, an IATP symposium focusing on 'Pathology Working Groups' and an ESTP expert workshop on 'Female Reproductive System' will take place immediately before and after the congress, respectively, although separate registration will be needed for both events.

We will also welcome a trade exhibition, including new equipment, technologies, and services. The social program will include the welcome reception (23<sup>rd</sup> September 2025), congress dinner (25<sup>th</sup> September 2025), and a celebration of the 40<sup>th</sup> anniversary of the BSTP (details to be confirmed).



The congress takes place in Manchester, United Kingdom from 23<sup>rd</sup> to 26<sup>th</sup> September 2025. Manchester is in northwest England with a notable history as a centre for textile manufacture in the 19<sup>th</sup> Century leading it to be the world's first industrialised city. In more recent times, Manchester has made significant contributions to science, engineering, politics, music, arts, and sport. There is much to see and do in Manchester, from world-famous football stadia, Castlefield Urban Heritage Park, John Rylands Library, People's History Museum, Science and Industry Museum, Imperial War

Museum North and much more. The city is also famous for The Curry Mile which features around 70 different Asian restaurants including Indian, Pakistani, Sri Lankan and Bangladeshi. Your trip won't be complete without a curry night.

For further information, abstract submission and registration, please visit congress website: <a href="https://www.bstp-estp-congress.eu">www.bstp-estp-congress.eu</a>

On behalf of the scientific organizing committee, it will be our pleasure and honour to welcome you all to the 2<sup>nd</sup> Joint BSTP/ESTP Toxicologic Pathology Congress in September 2025. We look forward to seeing you in Manchester!

With kind regards, Chairs of Scientific Organizing Committee

BSTP representatives
Jon Carter & Zuhal Dincer

ESTP representatives
Thomas Nolte & Ute Bach

### Toxicologic Pathology Training Program – the next step

Dear ESTP members,

The University of Veterinary Medicine Hannover (TiHo) has a long-standing cooperation with pathologists and scientists working in the pharmaceutical- and chemical industry acting as lecturers for doctoral students. In 2005, this cooperation was formalized in the

"Toxicologic Pathology Training Program" sponsored by the European Society of Toxicologic Pathology (ESTP) and associated with the yearly seminar "Classical examples in Toxicologic Pathology". This program was designed to give residents **ECVP** comprehensive introduction into Toxicologic Pathology and consisted of 18 one-day modules (6 modules per year), which were repeated and updated every three years. These modules described the morphology of organ systems and provided examples of toxicity, clinical pathology parameters, biomarkers, and carcinogenesis models. Thanks to the passionate commitment of the experienced speakers, numerous participants were motivated to work in the pharmaceutical or chemical industry or at contract research institutes after completing their doctoral thesis and ECVP residency.

The last cycle of modules, which had to be adapted due to the SARS-CoV-2 pandemic and was partly held as webinar, has been finished in the winter semester 2024/25. The next cycle of this successful program will take place from the summer semester of 2025 to the winter semester of 2027/28 and include 12 modules featuring diseases of laboratory animals, toxicopathology of the hepatobiliary system, drug development, alternative methods to animal experiments, molecular and digital pathology, and inhalation toxicity studies. The goal of this cycle is to significantly expand the outreach of the program and thus enable not only students from the TiHo to participate but also ECVP residents from other European training centers. Modules will take place in Hannover (Germany) and other European cities such as Barcelona (Spain) and Bern (Switzerland) in a hybrid mode to allow online participation. We hope to inspire young

academics in Europe to pursue a career as toxicologic pathologists, to promote the cooperation between the ESTP and other societies of toxicologic pathology in Europe as well as stimulate the collaboration between industry and academia. You can find more detailed information at our website:

https://www.tiho-hannover.de/klinikeninstitute/institut-fuerpathologie/aktuelleveranstaltungen/toxicologic-pathology-trainingprogram

If you are interested in contributing to this program, please get in touch with us.

With many greetings from Marburg and Hannover,

Simone Tangermann and Ingo Gerhauser

## **Introducing Kerstin Hahn: New ESTP Toxicologic Pathology Journal Liaison**



We are pleased to announce that Kerstin Hahn has assumed the role of ESTP Toxicologic Pathology Journal Liaison, effective at the beginning of this year. Her primary responsibilities include serving as a reviewer and associate editor for ESTP manuscripts submitted to the Toxicologic Pathology (TXP) journal, as well as facilitating communication between the journal's editorial team and ESTP chairs/authors.

Additionally, Kerstin will collaborate with chairs and authors to guarantee that manuscripts are properly submitted and formatted for publication in the TXP journal, which includes verifying categories and ensuring accurate titles and disclaimers in accordance with the ESTP CRSS.

Kerstin received her DVM and PhD in neuroscience and neuroinfectiology from the University of Veterinary Medicine Hannover, Germany. She completed her pathology residency and ECVP board certification at the University of Bern, Switzerland and worked as a postdoc in molecular oncology at the University of Bern and the Netherlands Cancer Institute, Amsterdam. Currently, Kerstin is a toxicologic pathologist at Roche in Switzerland, focusing on CNS targeted compounds, gene therapy and the implementation of spatial omics methods for toxicology and discovery pathology readouts.

With her extensive experience in publishing, Kerstin is eager to use her expertise to strengthen the link between ESTP and the Tox Path journal. She looks forward to supporting the publication of your manuscripts in Toxicologic Pathology.

### Pathology 2.0 Committee Year-End Meeting

The Pathology 2.0 committee held its year-end meeting in December 2024. The meeting was open to all ESTP members and some non-Pathology 2.0 members participated as well. During the meeting subgroups shared their 2024 achievements (e.g. two manuscripts have been accepted for publication coming from different subgroups, review of the year 2023 award from Tox Path has been received by one subgroup) and discussed goals for 2025 (Points-to-consider publication, webinars, sessions at congresses. The committee has decided to change the frequency of general meetings to twice per year, with one meeting, if possible, to be held face-toface at the ESTP congress. The upcoming general meetings will also be open to the entire ESTP community and announced by the ESTP secretary.

Career Transition Support Group Following the success of last year's webinar "From Toxicologic Pathologist to Project Toxicologist: Navigating Career Transitions," we surveyed the ESTP community to capture the level of interest in this topic and assess the potential appetite for creating a working group. The survey had a high participation rate with 120 ESTP members responding. Among them 83 responders worked for more than 10 years in the field of toxicopathology and 25 responders between 1 and 5 years. The questions "Do you experience working as a project have toxicologist" resulted in 25 answers "yes, many projects", 15 "yes, some projects", 24 "yes, couple of projects" and 54 "no". The questions

"did you attend the webinar from toxicologic pathologist to project toxicologist" answered 81 with no. The questions "Would you like to receive more information or training on what is Toxicologic **Pathologist** for transition into the role of Project Toxicologist?" was answered with yes by 70 responders and the questions "Would you be interested in attending courses or webinars related to topic 'toxicology for pathologists'?" was answered with yes by 95 responders. The survey results indicated significant interest, and 28 members expressed their willingness to participate in the creation of a subgroup. An kickoff meeting was already held last February with the interested members where preliminary ideas and a potential path forward were discussed. The group will continue working to identify potential educational niches where we can provide value and further support our community and is always open for more people interested in this topic.

Josep Monne and Dirk Schaudien Co-Chairs Pathology 2.0 Committee

# The future of "Guess What": Results from the Survey and Thoughts for a New Concept

Dear Colleagues,

as complained about several times over the past years, the participation at our ESTP "Guess What" Section is rather low, and to collect interesting cases is arbitrary, i.e. most of them are submitted by the same people. Before terminating our efforts to provide this kind of as we think – valuable continuous education, we have started a survey among the ESTP

membership last year to hear your opinion and gain information on the frequency of visits and participation on the "Guess What" Section, and of course, hoped for proposals to make it more attractive and user-friendly.

Honestly, the result was disappointing: Out of our membership consisting of 320 people we received only 20 responses (6.25%). A big THANK YOU therefore to those that have answered! Time constraints might have been a reason for many to not respond. However, participants of the survey needed between 54 seconds and 13 minutes to fill out the questionnaire and answer to the 19 questions. The vast majority was done within two to three minutes!

Four colleagues (20%) were not aware of the existence of the "Guess What" Section. Nine colleagues work in ToxPath for more than 10 years, three between 5 and 10 years. This means 12 pathologists can be considered as experienced and thus, represent the "original target group" of our "Guess What"-Cases. Six colleagues seem to be younger and work between 1 and 5 years in our field, while 2 of the responders do not work in ToxPath but have an interest in our cases.

The question "Do you look at the ESTP Guess What cases on the ESTP homepage" was answered with "never" by 6 persons, another 6 colleagues do it irregularly but less than once a year, and 8 once a year. Fifty percent of the responders never sent in a diagnosis, 7 did it once and 3 colleagues are regular participants and sent in a diagnosis multiple time (thank you!).

Obviously, the function "solution overview" in the "Guess What" section is not used or even not known by the majority of our responding colleagues, and only two persons said they are using it. This overview lists the 31 cases that have been presented over the last 20 years showing the main feature of the lesion, the descriptive term and the actual INHAND terminology. You should have look on it, maybe you find an answer on something you wanted to know already for years...

Of the 14 who answered the question, 13 think the number and quality of the given pictures are sufficient to solve the case. One person would prefer to have a scan to go more into detail. This is something that already has been frequently discussed within the team but unfortunately is technically not possible without possible negative influence on the ESTP homepage security.

The question about the difficulty grade was answered by two younger colleagues (1 to 5 years in the field) that they would prefer cases that are easier to diagnose. Four answers said that the difficulty grade is just right, and 3 colleagues clearly said that the cases should not be easy ones.

About half of the respondents found that the "Guess What" cases are a valuable contribution to their work. Interestingly, only one of these 8 used the function "solution overview". One colleague working in the field for more than 10 years answered that the ESTP "Guess What" Cases are of no value for the ToxPath community (that somewhat hurts...). Luckily, 16 of 19 colleagues recognized our intention to present useful cases.

Regarding the question whether the presentation of the ESTP "Guess What" cases conceptionally should be changed, 3 persons find it not necessary. Most do not know, but from one colleague the proposal came to present the cases

at ESTP meetings as a drop out session or during a break or even as a standing mystery slides talk with voting option. Another person said that the time between posting and resolution takes too long and intermittent hints could be helpful. A release of the cases on social media was another suggestion.

Websites similar to ESTP's "Guess What" (STP – ToxPathPic and AskJPC) are visited by seven of the responding colleagues. Discontinue of the ESTP "GuessWhat" section would be missed by one single colleague while 5 had no problem with its termination. The others did not know. The clearest answer came to the question if anybody would like to join the "Guess What" Team: 18 (90%) colleagues said "NO", and 2 politely avoided to give an answer... Probably all of them realized the amount of work and the occasional frustration providing this effort to our membership.

Since we have received a low number of responses, we can conclude that there is not an overwhelming interest in our "Guess What" activities. Nevertheless, 15 of the 20 colleagues would like to be informed by an ESTP email and/or LinkedIn when a new case is opened for discussion, while the announcement on the homepage is alert enough for the others.

The results of this survey may be interpreted in different ways. It becomes clear that something has to be changed to reduce the amount of time which is invested by those that provide the case. So far, the preparation of the solution takes most of the effort if it shall be scientifically of benefit. The ESTP Board had indicated that it would prefer the "Guess What" Section to be a tool for younger colleagues for the preparation of the Board Examinations. This would be a complete turnaround from the original idea to provide a

forum for rare and even unknown lesions to use the potential of knowledge which is around in our community.

In the last months we have considered ideas in different directions. This includes termination of the "Guess What" section as well as presenting a spectrum of "normal" peculiarities in laboratory animals. The frequency of cases shall be increased over the year and the solution of the case is planned to be available immediately. One possibility is also to have a kind of moderated short discussion on LinkedIn. Of course, this will need someone to care for, and we happily appreciate the recent application of Massoud Rezaee who volunteered to join our group!

For those that have read this article to the end and maybe have missed the survey: You are very welcome to provide us with your ideas and suggestions how to maintain our goal of continuous education for the value of the ToxPath community.

We are looking forward to hearing from you.

Sincerely your "Guess What" Team: Matthias Rinke, Susanne Rittinghausen, Dirk Schaudien, our new member Massoud Rezaee as well as our ESTP Webmaster Rupert Kellner, who at the end has to find the technical solution.

### **2025 ESTP Publication Award – Call for Papers or Theses:**

Dear ESTP members,

The ESTP Award Committee is pleased to announce the call for submissions for the 2025 ESTP Publication Award.

Since its inception in 2002, the ESTP has been dedicated to promoting the significance of

toxicologic pathology as a specialized discipline in Europe. In recognition of outstanding contributions to this field, we annually honor impactful publications, whether they are papers or theses.

We invite nominations for exceptional publications that were published during 2024 - 2025. The deadline for submission will be May 31, 2025.

The ESTP Award Committee will evaluate all submissions, and the most distinguished publication will receive an award of 1,500 Euros. This year's award will be presented at the 2025 ESTP annual meeting in Manchester, UK, September 23 – 26, 2025. Attendance at the awards ceremony is mandatory for the recipient, and the admission fee for the meeting will be waived.

We encourage all members to consider submitting their work or nominating deserving colleagues. Publications by the ESTP or a subcommittee of the ESTP are not accepted for submission. For submissions and further inquiries, please contact the chair of the ESTP Award Committee, Dr. Theresa Brömel, via the ESTP contact form.

We look forward to celebrating the innovative research and contributions to the field of toxicologic pathology with you.

Theresa Brömel

The Award Committee:
Hans Harlemann
Johannes Junginger
Robert Klopfleisch
Régis Masson
Thomas Nolte
Fernando Romero-Palomo

### Reflections on the Classic Examples in Toxicologic Pathology XXXII March 20 and 21, 2025

by Richard Haworth

The Classic Examples meeting in Hannover feels different from other meetings. All of us are now used to attending webinars and other virtual meetings. We are aware of their convenience but also their shortcomings. In contrast, this inperson seminar is designed to engage participants more actively than almost any other conference I can think of. You can view whole slide images (WSI) in advance of the meeting, test your diagnostic skills and come prepared with questions. Interesting topics, time for discussion and detailed handouts of each case make this a powerful educational experience. In addition, the organisers ensure there is plenty of time to chat to other attendees and network over cake and coffee. The meeting, which attracts experienced and trainee pathologists, was well attended (115 people).



This year the agenda was a varied mix of interesting and relevant cases covering different

modalities, study types, pharmacology and species. Svenja Hartung and Annette Romeike presented the first case which showed a fascinating range of tissue changes in cynomolgus monkeys after administration of a IL-2-linked modified anti-PD1 antibody. Cardiomyocyte and skeletal/smooth muscle degeneration with associated myocyte inflammatory cell infiltrate and changes in lymphocyte populations in spleen and thymus were the most striking lesions. Then, Thomas Nolte presented a case of atypical lymphoid hyperplasia and thymomas induced in a 2 year rat study by a small molecule RORyt inhibitor cytokeratin and the value of pan immunohistochemistry (IHC) in characterising epithelial cell changes. Babu Gangadharan introduced us to the world of developmental neuropathology by showing cerebral periventricular heterotopia, cerebellar external granular layer persistence and delayed regression of the cochlear epithelial ridge in rat following maternal hypothyroidism. pups Béatrice Gauthier showed how IHC and image analysis increased sensitivity over standard H&E evaluation, for detection of Kupffer cell reduction in rats and dogs given a CSF1R inhibitor. The role of Kupffer cells in enzyme clearance was linked in these studies to an increase in serum AST and ALT in the absence of histopathological evidence of hepatocyte degeneration and necrosis. The last talk of the day was given by Stephanie Klein who provided histopathology evidence and mechanistic insight as to how single cell hepatocellular necrosis and other liver changes in mice and rats given GalNac-conjugated siRNAs can be the result of off- target effects.

The second day was opened by Venkatesha Udupa who presented a case of a drug metabolite which caused non-cationic amphiphilic (CAD) drug-induced phospholipidosis (PLD) in liver, kidneys and skeletal muscle of rats and gallbladder of dogs, but not mice. LAMP-2 and transmission electron microscopy were used to confirm PLD. Then Charlotte Maria Dalsgaard presented on hydroxypropyl beta cyclodextrin (HPbetaCD)-induced findings in the urinary tract. This compound, which is added to formulations to enhance the solubility, stability, and bioavailability of lipophilic/hydrophobic drugs, was tested subcutaneously in chronic rat and dog studies. Vacuolation and karyomegaly of the rat renal tubular epithelium and vacuolation of the dog renal pelvic urothelium was observed. This vacuolation is understood to represent hydropic swelling of the phagolysosome.

Frank Geoly was unfortunately unable to attend the meeting, but Thomas Nolte and Charlotte Lempp valiantly stood in and gave his presentation. In the two-year rat carcinogenicity study with abrocitinib, a Janus Kinase 1 (JAK1) inhibitor indicated for the treatment of atopic dermatitis, a test article-related increase in benign thymoma was observed in female Wistar Han rats. This tumour, which occurs spontaneously at higher incidence in female Wistar Han rats relative to males and other strains. is also induced by other immunosuppressive drugs. Although the mechanism for thymoma induction by JAK inhibitors in rats is not known, there is no evidence of increased thymomas in patients receiving these medicines.

We were then given an insight to the diagnostic challenges in medical histopathology related to infectious complications in immunocompromised transplanted patients by Jan Bräsen. The risks of polyoma and hepatitis E virus renal infection were discussed. The final talk was given by Anna Maria Giusti who presented immune complex-mediated serositis in non-human primates induced by mAbs. For those examining mAb studies, recognising and interpreting immune complex disease is a frequent and important step in study evaluation and subsequent risk assessment. Many of the wide diversity of changes encountered are not yet in the literature and hearing from others who have applied immunohistochemistry and other study endpoints to generate a weight of evidence is particularly valuable.



In summary, it was a very well organised meeting. It was enjoyable and informative. On behalf of participants, we thank Prof. Andreas Beineke for hosting this Seminar and the scientific organisers Thomas Nolte and Charlotte Lempp. Thank you also to Theresa Störk and colleagues who contributed to the smooth running on site at the Hannover vetschool. Look out for dates for the next Classic Examples and join us in 2026!

#### **Announcement from the SFPT**



The SFPT society is delighted to announce its upcoming annual congress which will be held on May 14 and 15 2025 at Sanofi's facility in Vitry sur Seine near Paris.

The scientific program can be found on our website. Please note that all presentations will be in English and a supplementary program detailing registration procedures, access modalities, and accommodation options will be released shortly.

With the link to our brand-new website: https://toxpathfrance.org/congres/